Point Biopharma Is A Radiopharmaceutical Company Focused On Developing Next Generation Radioligand Therapies For Cancer Treatmentas A Wholly Owned Subsidiary Of Eli Lilly And Companypoint Was Acquired In December 2023 For $1 4 Billionthe Company Specializes In Precision Oncologyutilizing Targeted Radiation Delivery To Treat Various Cancers Point Biopharma Operates A 180 000 Square Foot Manufacturing Facility In Indianapolis And A Research And Development Center In Torontoits Product Offerings Include Late Stage Candidates Like Pnt2002Aimed At Metastatic Castration Resistant Prostate Cancerand Pnt2003Which Targets Gastroenteropancreatic Neuroendocrine Tumorsthe Company Also Has A Preclinical Pipeline With Additional Radioligand Therapy Candidatespoint S Manufacturing Capabilities Support Both Clinical And Commercial Scale Productionensuring Quality And Efficiency In Its Operations
No conferences found for this company.
| Company Name | Pnt Pharma |
| Country |
India
|
| Address | N/A |
| Telephone | N/A |
| N/A |
